Brief: Skye Bioscience Completes Enrollment of Phase 2a Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
26/02/2024 12:07
Feb 26 (Reuters) - Skye Bioscience Inc SKYE.PK :
* SKYE BIOSCIENCE COMPLETES ENROLLMENT OF PHASE 2A CLINICAL
TRIAL
OF SBI-100 OPHTHALMIC EMULSION IN GLAUCOMA AND OCULAR
HYPERTENSION
Source text for Eikon: ID:nGNXZRWwj
Further company coverage: SKYE.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Skye Bioscience
See all newsBrief: Skye Announces Cohort Review Committee Approved Opening Of Cohort 2 Based On Favorable Safety Data From First Four Participants Treated In Cohort 1
U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis
U.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
U.S. STOCKS ON THE MOVE-Energy firms, Estee Lauder, HMH Holding
Skye Bioscience rises as it begins testing higher doses of obesity drug